Rohit Jain, MD
@rohitjainMD
Followers
281
Following
108
Media
2
Statuses
66
GU Medical Oncologist @ Weill Cornell Medicine
New York, USA
Joined June 2019
RT @binaytara: A wonderful group here at #AtlantaGU25🦸! @rohitjainMD of @WeillCornell , @arnabguonc from @ONealCancerUAB , and Dr. Jacqueli….
0
3
0
RT @WCMGIcancer: Join us in our social media welcome for #GI medical oncologist Dr. Rutika Mehta (@rutikamehtaMD)! Dr. Mehta is available f….
0
3
0
RT @WCMGUcancer: Dr. Rohit Jain (@rohitjainMD) was first author on #research from @ASCO #GU25 evaluating erafitinib + enfortumab vedotin fo….
0
5
0
RT @rutikamehtaMD: Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers ht….
academic.oup.com
FGFR2 overexpression or amplification has become an area of interest for the development of new targeted-based treatment. This article focuses on the genom
0
3
0
RT @VJOncology: May is #BladderCancerAwarenessMonth 📣 . And we are passionate about bringing you the latest news and updates 🎥 🗞️ . @rohitj….
vjoncology.com
Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, comments on the novel developments in the field of antibody-drug conjugates (ADCs) for urothelial carcinoma....
0
1
0
"A girl in a flowing white dress floating gracefully into a dreamy sky filled with stars and colorful clouds at sunset.". Try Grok Imagine, free for a limited time:.
14
6
76
RT @GUOncologyNow: A study from @rohitjainMD and colleagues presented at #GU24 showed that #cabozantinib plus #pembrolizumab exhibited a ma….
0
1
0
RT @OncLive: First-line pembrolizumab plus cabozantinib was efficacious and had a manageable toxicity profile in patients with advanced uro….
0
2
0
RT @OncLive: Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial c….
onclive.com
Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.
0
2
0
RT @sonpavde: #GU24 #bladdercancer highlights in my opinion: 1) AMBASSADOR Phase III @apolo_andrea-improved DFS for adjuvant pembro x 1 yea….
0
32
0
RT @sonpavde: #GU24 #bladdercancer #urothelialcarcinoma preview: PemCab Phse II #clinicaltrial- Cabozantinib + pembrolizumab as first-line….
0
9
0
RT @neerajaiims: Just in @NatureMedicine👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer👉enza + tala vs.….
0
121
0
RT @CancerNetwrk: When Jeffrey Ehas was diagnosed with cancer, he and his wife, Lauren Ehas, turned to Moffitt Cancer Center in Tampa, Flor….
cancernetwork.com
A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.
0
1
0
RT @FDavaro: Read our mini-article on what a urologist needs to know in the management of ICU related AEs in NMIBC. Critical for urologists….
0
5
0
RT @sonpavde: Monoclonal antibodies (non-ICI) for metastatic #urothelialcarcinoma #bladdercancer-we review previously investigated targets….
tandfonline.com
The treatment landscape for advanced-stage, unresectable or metastatic urothelial carcinoma (mUC) has shifted dramatically over a short period of time, with new therapeutic agents available for cli...
0
6
0
RT @OncLive: WATCH: Rutika Mehta, MD, MPH, discusses which pts w/ ESCC may benefit most from the different frontline treatment options avai….
onclive.com
Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment develo...
0
1
0
RT @Jcj84Jeremy: Dr Mehta giving updates in gastroesophageal cancer at the 1st annual Highlights in GI Oncology. @drjasonstarr @HaniBabiker….
0
3
0
RT @AbhiTrip87: @montypal @NazliDizman @LuisMezaco @PauloBergerot @TGen @cityofhope @montypal What an inspiring thread for all young invest….
0
3
0
RT @FrontOncology: 📣 Check out this report of chemo refractory metastatic penile SCC with extreme durable response to pembrolizumab by @Jad….
0
7
0